Company Overview
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -4.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -4.30% |
Stock Price Performance
| 1 Year: | -66.01% |
| 6 Months: | -45.50% |
| 3 Months: | -55.19% |
| 1 Month: | -14.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 75.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HUMA Humacyte, Inc. R2KPHARMA | 0.60 | -0.95 | $161.78M | 0.00% | -110.35% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 517.00K | 301.00K | 753.00K | 495.00K |
| Operating Income | - | - | -17.21M | -19.77M | -19.27M | -20.54M | -21.76M | -18.53M | -23.49M | -22.51M | -26.73M | -24.62M | -26.58M | -29.50M | -30.23M | -23.18M | -29.73M | -24.39M | -28.93M |
| Net Income | -17.67M | -14.88M | -17.76M | -20.30M | -17.20M | -31.56M | -19.83M | 36.87M | -25.28M | -36.97M | -22.71M | -26.00M | -31.90M | -56.66M | -39.20M | 39.14M | -37.66M | -17.51M | -17.62M |
| Diluted EPS | - | - | -3.07 | -3.46 | -2.89 | -0.72 | -0.19 | 0.35 | -0.25 | -0.36 | -0.22 | -0.25 | -0.29 | -0.48 | -0.33 | 0.28 | -0.24 | -0.11 | -0.09 |
| R&D Expense | - | - | 14.69M | 15.14M | 14.57M | 15.39M | 16.31M | 14.65M | 17.34M | 17.28M | 20.54M | 18.55M | 21.26M | 23.75M | 22.93M | 15.42M | 22.01M | 17.27M | 19.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 2.04M |
| Operating Income | -64.60M | -81.21M | -84.58M | -100.05M | -114.40M | -108.14M |
| Net Income | -66.52M | -26.48M | -11.96M | -110.78M | -148.70M | -40.83M |
| Diluted EPS | -11.54 | -0.66 | -0.12 | -1.07 | -1.26 | -0.26 |
| R&D Expense | 54.08M | 61.34M | 63.26M | 76.55M | 88.60M | 69.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.69M | 286.53M | 204.30M | 128.22M | 137.87M | 116.37M |
| Total Equity | -288.79M | -350.32M | 122.17M | 116.93M | 13.55M | -52.67M | 3.11M |
| Cash & Equivalents | - | 39.93M | 217.50M | 149.77M | 80.45M | 44.94M | 50.50M |
| Long Term Debt | - | - | 30.00M | - | - | 0 | 35.44M |
| Total Liabilities | - | 36.02M | 164.36M | 87.37M | 114.68M | 190.54M | 113.26M |
| Current Liabilities | - | 11.23M | 11.05M | 19.58M | 18.44M | 19.95M | 18.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -55.57M | -81.19M | -71.13M | -73.31M | -98.12M | -105.04M |
| Investing Cash Flow | -268.00K | -8.22M | 4.84M | -173.00K | -1.57M | -884.00K |
| Financing Cash Flow | 2.05M | 266.98M | -1.45M | 4.51M | 114.18M | 61.49M |
| Capital Expenditure | -318.00K | -220.00K | -1.05M | -2.28M | -1.57M | -884.00K |
| Free Cash Flow | -55.89M | -81.41M | -72.18M | -75.58M | -99.69M | -105.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -5,306.0% |
| Net Margin % | - | - | - | - | - | -2,003.6% |
| ROE % | 19.0% | -21.7% | -10.2% | -817.8% | 282.3% | -1,313.4% |
| ROCE % | -67.7% | -29.5% | -45.8% | -91.1% | -97.0% | -110.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Antipodes Partners Ltd. | 3.64% | 10.10M | $6.57M |
| 2 | Vanguard Capital Management LLC | 3.64% | 10.11M | $6.57M |
| 3 | Alyeska Investment Group, L.p. | 2.17% | 6.02M | $3.92M |
| 4 | Davidson Kempner Capital Management LP | 1.80% | 5.00M | $3.25M |
| 5 | Blackrock Inc. | 1.74% | 4.84M | $3.15M |
| 6 | Great Point Partners LLC | 1.35% | 3.75M | $2.44M |
| 7 | UBS Group AG | 1.02% | 2.84M | $1.85M |
| 8 | AQR Capital Management, LLC | 0.93% | 2.60M | $1.69M |
| 9 | Geode Capital Management, LLC | 0.79% | 2.19M | $1.42M |
| 10 | Millennium Management Llc | 0.69% | 1.91M | $1.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HUMA
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQZV9Ebl92NTJNYlBjSG94WW9kZXRRTFVjOU1ZNVRCZW5qdHRZeGlMRmxWRUdtSGdoeUhHR3FXdGY4SWhQbmVHRDVCOTRHX1VMcFhIb1FKZlMyV0VlVVJzWHNYV2pITzRfMDZDa2VvVnJwQ3c2R1RyblJ6b2tVWHY5UDVWUGFMdDV6TldOX2…
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOR2VOMUVtRUNKdGhhQWxXNGpYM1dqRGtsWFpXM01jek5EQzZFb3NEYVhSR2k3Zl9WWm96aXd6WnhJekVOQjBXVXNJUklHWE5FMnlNS3h5ZjdHT2ExSmgxNGtSZTVKdXZQbWtvZFV3RFdoNWlqT1YyRnR2TGJKbHpjOGFBa1U0dVJpV2MzTW…
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOWjVMMERMV2xwVkNLQkhaa0tFTkl0TVNzODJRRU5ad2libWNId296MFJCR1dZcnFXLWY3VHpodzA1M3NVbGtPNTYyM3VHdjkyWmV4dHExZVJ1YnpSdTdIdWliMmxwUWw2VXlIOHkyWjA4Qnk3ZDh4aWgwRXZkSktuQTl5ZFBGMFR5S1oya2…
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNN2FUeldxT1ltT3d0dWE2THBrWnp1WWRORlZBdEZ2MlNYdzRHUmZ0MzRDSDNLNGtudl9aVUFVclRhQ0wyZHBZdV8wQXZCbHVBMGx5MHE5S2l1Uy0ya2Fna1kzMFpHSDRjb1RWeUVuOWZybmc3RmVVM19yRVZlaklLMzNaMGNSaHFtazZqRz…
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMmNZbVNfSnViZ3BPY1RheHliOVhHYm9Dd1U2c2dXU3JHM0FYVVBidFh0VENvZF9ONE1XWGpPUUN3YWVJWlVVSnpkRVhIdjEza3ZHdVd4dmwzLXhOekcxbDFSUG83dC05cjhVVzdzaWVLb19xUWtfNmU0Ynpsc3gycDVDVTFMYS1vaVNYR2…
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQUlpnY0pUaFhxeWoyZkpOTUVHcXo3NlNMTF9vY2VVdlVKUFFncDF1bGVVR2llb3ZraUtMMjU0RlYwMDNoVEtFdmNSQ2RHNVV5RjByQ2M5TkVFT2lGSmc2YnEyZzJBY2xUTWxnN1Q1c3BGQXRpZldCUmRHdFVNenhLb0UxczJCT0JJclVVQ2…
HUMA — Frequently Asked Questions
What is the current share price of Humacyte, Inc. (HUMA)?
As of 2026-09-07 16:24 PDT, Humacyte, Inc. (HUMA) trades at $0.60 on NasdaqGS. Its 52-week range is $0.55 to $2.48.
What is the market capitalisation of HUMA?
Humacyte, Inc. (HUMA) has a market capitalisation of $161.78M on NasdaqGS.
What is the P/E ratio of HUMA?
HUMA trades at a trailing price-to-earnings (P/E) ratio of -0.95. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 13.81.
Is HUMA a good stock to buy?
This page provides a data-driven analysis of Humacyte, Inc. (HUMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.